Press Release - 2025-09-11
Press Release - 2025-07-17
Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress
Press Release - 2025-04-24
Seaport Therapeutics Presents New Preclinical Data on SPT-320 (Glyph Agomelatine) at the Society of Biological Psychiatry (SOBP) Annual Meeting
Press Release - 2025-03-31
Seaport Therapeutics to Participate in Upcoming Investor Conferences in April
Press Release - 2025-03-11
Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair
Press Release - 2025-03-03
Seaport Therapeutics to Participate in Two Upcoming Investor Conferences
Press Release - 2025-02-21
Seaport Therapeutics Presents New Meta-Analysis Examining Correlations Between Clinical Trial Design Factors and Placebo Response in Major Depressive Disorder Studies
Press Release - 2025-02-12
Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Platform
Press Release - 2025-01-06
Seaport Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Press Release - 2024-12-11
